Sulfuric Acid

Sulfuric Acid

SCHEMBL128048

C=CC(=O)OCCN(C)C.O=S(=O)(O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.47
CHRM1 known ✓ P11229 1/20 0.47
CHRM3 known ✓ P20309 1/20 0.47
TSHR P16473 7/20 0.48
HPGD P15428 1/20 0.48
ALDH1A1 P00352 5/20 0.48
TP53 P04637 3/20 0.48
HIF1A Q16665 3/20 0.48
CYP3A4 P08684 3/20 0.48
HSD17B10 Q99714 1/20 0.48
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA4 P43681 1/20 0.47
THRB P10828 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
DNM1 Q05193 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL27667403 1.00 TSHR (0.48) TSHRHPGDALDH1A1TP53HIF1A
Sulfuric Acid SCHEMBL28351009 0.98 TSHR (0.47) TSHRHPGDALDH1A1TP53HIF1A
Sulfuric Acid SCHEMBL28251440 0.98 TSHR (0.47) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL17003984 0.95 TSHR (0.47) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL28515730 0.93 TSHR (0.50) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL15115 0.92 TSHR (0.56) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL127382 0.91 TSHR (0.44) TSHRHPGDALDH1A1TP53HIF1A
Ethylene SCHEMBL8397415 0.90 TSHR (0.54) TSHRHPGDALDH1A1TP53HIF1A
Hydrochloric Acid SCHEMBL130714 0.90 TSHR (0.54) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL28612529 0.90 TSHR (0.54) TSHRHPGDALDH1A1TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070397-A Use of fast reverse cationic emulsion polymers with polyvinylamines as retention and drainage aids 凯米拉公司 2026-05-19 CN claimed
EP-4739418-A2 ONE-PASS DEOXYGENATION METHOD FOR POLYACRYLAMIDE PRODUCTION KEMIRA OYJ (FI) 2026-05-13 EP claimed
EP-4728136-A1 STRENGTH SYNERGY BETWEEN POLYMER AND PAPERMAKING STRENGTH AID Ecolab USA, Inc. (US) 2026-04-22 EP claimed
EP-4716777-A2 USE OF AMPHOTERIC EMULSION POLYMERS WITH STRENGTH RESINS AS RETENTION AND DRAINAGE AIDS KEMIRA OYJ (FI) 2026-04-01 EP claimed
US-12553188-B2 GPAM compositions and methods KEMIRA OYJ (FI) 2026-02-17 US claimed
EP-4683950-A1 DUAL EMULSIFICATION OF ALKENYL SUCCINIC ANHYDRIDE TO IMPROVE SIZING PERFORMANCE AND STABILITY KEMIRA OYJ (FI) 2026-01-28 EP claimed
US-20250215649-A1 HIGH MOLECULAR WEIGHT GPAM WITH ANIONIC POLYSACCHARIDE PROMOTER KEMIRA OYJ (FI) 2025-07-03 US claimed
CN-115516031-B GPAM compositions and methods 凯米拉公司 2025-06-17 CN claimed
US-20250137200-A1 HIGH MOLECULAR WEIGHT GPAM WITH ANIONIC POLYMERIC PROMOTER KEMIRA OYJ (FI) 2025-05-01 US claimed
EP-4256009-B1 OIL-IN-WATER EMULSIONS QUADRISE INT LTD (GB) 2025-04-09 EP claimed
US-7378023-B2 Adding a cationic polymer to activated sludge; improving flux through a membrane in the MBR; reducing fouling NALCO COMPANY (US) 2008-05-27 US claimed
US-20080060996-A1 Method of improving membrane bioreactor performance ECOLAB USA INC. 2008-03-13 US claimed
EP-1885656-A1 A METHOD FOR IMPROVING FLUX IN A MEMBRANE BIOREACTOR Nalco Company (US) 2008-02-13 EP claimed
EP-1734011-A1 A method for improving flux in a membrane bioreactor Nalco Company (US) 2006-12-20 EP claimed
WO-2006130163-A1 A METHOD FOR IMPROVING FLUX IN A MEMBRANE BIOREACTOR NALCO COMPANY (US) 2006-12-07 WO claimed
US-20060272198-A1 Method for improving flux in a membrane bioreactor ECOLAB USA INC. 2006-12-07 US claimed
US-20060003899-A1 Drilling fluid and methods of use thereof NEW WEST DRILLING FLUIDS INC. (CA) 2006-01-05 US claimed
US-6753388-B1 WATER-SOLUBLE, CROSSLINKED POLYMERS COMPRISING (CO)MONOMERS OF (METH)ACRYLAMIDE, (METH)ACRYLIC ACID, SODIUM (METH)ACRYLATE, AMMONIUM (METH)ACRYLATE, 2-ACRYLAMIDO-2-METHYLPROPANESULFONIC ACID, AND/OR DIALKYLAMINOALKYL (METH)ACRYLATE OR SALTS NALCO COMPANY 2004-06-22 US claimed
WO-2004050791-A1 DRILLING FLUID AND METHODS OF USE THEREOF GENESIS INTERNATIONAL OILFIELD SERVICES INC. (CA) 2004-06-17 WO claimed
CN-1257512-A Preparation of water soluble polymer dispersions from vinylamide monomers NALCO CHEMICAL CO (US) 2000-06-21 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12553188-B2 GPAM compositions and methods PGM2, SLC6A9, GNMT CHRM2 680/4885CHRM1 848/4885CHRM3 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.